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We report a case of a 54 year old patient with Multiple Myeloma (MM) and chronic HCV infection. In
2005 MM was diagnosed and a chemotherapy was prescribed. Before starting treatment a chronic HCV
infection was found. When she came to our Institution for a second opinion, chemotherapy treatment
was not considered immediately necessary so the patient was treated for the HCV chronic infection
(Pegilated alpha-Interferon 180 μg/week and Ribavirin 1000 mg p.o./day). After one month of treatment
she presented a reduction of Bence Jones protein (BJ) that further decreased in the following three
months. The antiviral treatment was suspended after six months and a re-evaluation showed a complete
viral response and a regression of MM. Sixty-eight months after the end of antiviral treatment the patient
is asymptomatic and presents a condition compatible with an M-GUS. While the association between
HCV infection and non-Hodgkin's lymphoma is consolidated and it is clearly demonstrated that antiviral
treatment in these patients can induce a high proportion of partial and complete remission, a similar
effect was never described in MM. The response obtained in our patient may suggest a possible a role of
HCV in the pathogenesis of MM.
& 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.It is well demonstrated that chronic Hepatitis C Virus (HCV)
infection can be associated to non-Hodgkin's lymphoma (NHL)1
and that antiviral treatment can produce NHL regression in HCV-
related forms.2,3 We observed a case of Smoldering Multiple
Myeloma (SMM) and hepatitis C in which a clear regression of
SMM followed successful antiviral treatment.
In a 54 year old woman routine blood tests revealed, in January
2005, a monoclonal IgG-k (1.87 g/dl). Bence Jones protein (BJ) was
positive, with free k light chains 1.20 g/24 h. No bone lesions were
found and the bone marrow biopsy showed 20% plasma cell
inﬁltration, restricted for kappa light chains. Renal function was
normal while alanine transaminase (ALT) and aspartate transami-
nase (AST) were elevated. An increased level of AST, ALT and
gamma-glutamyl transpeptidase (GGT) was indeed present since
1985, but further investigations were not previously performed.
The patient was considered stage IA Multiple Myeloma (MM),
according to Durie and Salomon criteria, so no therapeutic
approach was chosen.
In the following months BJ progressively increased, reaching,
in September 2005, 5.7 g/24 h, conﬁrmed in multiple controls.t to report.
echnology and Hematology,
Rome, Italy.
ni).
-NC-ND license.The bone marrow needle biopsy and aspirate conﬁrmed a plasma
cell inﬁltration of 20%, in absence of anemia, renal impairment,
bone lesions. The Fish (ﬂuorescence in situ hybridization) analysis
revealed deletion 13q14 in 49% of plasma cells. The patient was
considered as having MM stage IIA, and a treatment consisting
of vincristine, adriblastine and dexamethasone (VAD) was
prescribed. Before starting treatment a chronic HCV infection
was demonstrated, with b1 genotype and 45105 Ul/ml viremia.
Liver biopsy found focal periportal low grade lymphoid inﬁltration
with peacemeal necrosis, low portal ﬁbrosis, concluding for
chronic hepatitis with a slight degree of activity (1st degree
1st phase). Liver echography showed a diffuse hyper-reﬂecting
structure.
At this point the patient came for a second opinion to
our Institution; she was asymptomatic, so the anti-myeloma
chemotherapy was not considered immediately necessary and an
antiviral treatment with pegilated alpha-interferon (IFN) 180 mg/
week and ribavirin 1000 mg p.o./day, was started.
One month after the start of antiviral treatment, a marked
reduction of the BJ (586 mg/24 h) was already observed.
Two months later, further BJ decrease was registered. The antiviral
treatment was discontinued after 6 months (July 2006). The end of
treatment re-evaluation documented a complete viral response
(HCV-RNA: neg, AST, ALT, GGT in the normal range), while
a signiﬁcant regression of myeloma was also observed: 24 h
proteinuria fell into the normal range, although free k light chains
Fig. 1. Simultaneous decrease of HCV-RNA copy number and Bence-Jones protein after treatment with Peg-Interferon and Ribavirin in a patient with HCV positive
micromolecular Multiple Myeloma.
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k component was also still present although reduced to 1.5 g/dl,
while all the other hematochemical parameters were normal.
Sixty-eight months after discontinuation of antiviral treatment,
the laboratory picture of the patient is unchanged, being compa-
tible with an M-GUS without any bone lesion nor any clinical
symptom; HCV-RNA is also negative, with normal liver function
and serology (Fig. 1).
Although an epidemiological association between HCV and
NHL is demonstrated,1 a similar association is not clearly evident
in the case of myeloma: indeed, in a case-control study, Bianco
et al. described a similar proportion of HCV positivity in myeloma
cases and controls.5
In HCV related NHL an antiviral treatment demonstrated a high
proportion of complete or partial response of lymphoma: in 2002
Hermine et al. documented lymphoma regression in 9 patients
with HCV-related splenic lymphoma with villous lymphocytes
(SLVL) 3; in 2005 Vallisa et al.2 reported respectively 58% and
16% of complete and partial hematological response after the
antiviral treatment with IFN and ribavirin.
Recently, a case control study revealed that HCV chronic
infection is also a risk factor in acute myeloid leukemia, but no
mention about regression of leukemia after antiviral treatment
is reported in literature at the present time.7 Although a not
signiﬁcantly higher prevalence of HCV correlation was described
in hematological disease other than NHL,5 no other reports about
disease regression after antiviral treatment were described.
Finally Arcaini et al.4 reported in 2011 the effect of antiviral
treatment in a large cohort of indolent HCV-related lymphomas
conﬁrming response in 77% of patients.
No experience on the effect of antiviral treatment in HCV positive
MM is reported to date. The clear response obtained in our case
suggests a possible role of chronic HCV infection also in MM, and a
possible relationship between viral response and regression of a
SMM to a condition of M-GUS. IFN exerts a documented intrinsic
anti-myeloma effect, as well as an anti-lymphoma effect: it isimpossible to exclude, therefore, a direct effect of the drug against
SMM. Limited improvement in terms of overall survival (7 months)
and relapse free survival (4.4 months)6 was demonstrated in a meta-
analysis by Fritz et al. about IFN as single agent in maintenance
therapy, while the efﬁcacy as mono-therapy in induction is limited.8
Moreover, in SLVL Hermine3 evidenced no response in patients
treated with IFN without HCV infection; in other experiences the
hematological response was correlated to the viral response, but not
to the interferon treatment. In conclusion, to our knowledge, this is
the ﬁrst case of regression of MM in an HCV positive patient
following antiviral treatment; nevertheless, further studies are
needed to conﬁrm this evidence.References
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